Searchable abstracts of presentations at key conferences in endocrinology

ea0009s2biog | Clinical Endocrinology Trust Visiting Professor Lecture | BES2005

Clinical Endocrinology Trust Visiting Professor Lecture

Jens Sandahl Christiansen

Jens Sandahl Christiansen, Medical Department M, Aarhus University Hospital, Aarhus, Denmark AbstractJens Sandahl Christiansen, MD, is professor of medicine and consultant endocrinologist at Aarhus University Hospital, Kommunehospitalet, Aarhus, Denmark. He graduated from Copenhagen University Medical School, and has been trained in diabetes and endocrinology in Copenhagen and Aarhus.Dr. Chr...

ea0037ew1.5 | Practical publishing advice | ECE2015

Open access

Christiansen Jens Sandahl

Open access publishing provides authors with the highest possible visibility for their work, as articles are made freely available online to everyone. Many funding bodies and institutions around the world are adopting policies, which require their researchers to publish their work open access. Do you know how open access policies affect you, and how to comply? This talk will clarify what open access publishing means, including the difference between green and gold open access ...

ea0026pl3 | Targets for the management of diabetes in 2011 | ECE2011

Targets for the managent of diabetes 2011

Christiansen Jens Sandahl

The Management of both type 1 diabetes (T1DM) and type 2 diabetes (T2DM) involves careful monitoring and treatment of hypertension, hyperlipidaemia and hyperglycaemia. Aggressive treatment of high blood pressure and high cholesterol has been proven effective in reducing mortality in both T1DM and T2DM. Various guidelines advocate certain values for blood pressure and for cholesterol to be aimed for. These cut-off values have been pushed downwards constantly during the last 3 d...

ea0011s91 | Contrasting practices in European endocrinology | ECE2006

Contrasting expenditure on expensive endocrine therapies – e.g. growth hormone

Sandahl Christiansen Jens

The clinical syndrome associated with profound growth hormone deficiency (GHD) in adults has now been established and recognised for more than ten years. The multiple physiological and metabolic actions of growth hormone (GH) has been shown in a logical way to translate into recognisable symptoms and signs in individuals lacking the hormone. Normalization of abnormal physiological and metabolic parameters secondary to GH-replacement therapy has been demonstrated beyond reasona...

ea0014p616 | (1) | ECE2007

Protein metabolism in a model of premature ovarian failure, Turner syndrome, and the impact of hormone replacement therapy

Gravholt Claus H , Riis Anne-Lene , Christiansen Jens Sandahl

Background: Several studies have documented an altered body composition in Turner syndrome (TS), a model of premature ovarian failure. Body fat is increased and muscle mass is decreased. The ovarian failure necessitates substitution with female hormone replacement therapy (HRT) for a number of years, and HRT induces favourable changes in body composition with a decrease in body fat and an increase in fat free mass. It is unknown how HRT affects protein metabolism.<p class=...

ea0011p571 | Growth and development | ECE2006

Mortality in growth hormone deficiency

Stochholm K , Gravholt C , Laursen T , Sandahl J , Green A

Aim: We aimed to describe mortality for both gender in children and adults, in Growth Hormone Deficiency (GHD).Materials and methods: Using three national registries: The Causes of Death Registry, The National Patient Registry, and The Cancer Registry, and The International Classification of Diseases as a filter, we identified a primary cohort of 9,131 patients. All had a high a priori risk of having GHD. All available hospital files (representing 90.2% ...

ea0037ep667 | Pituitary: basic and neuroendocrinology | ECE2015

GH therapy has a beneficial effect on HbA1c levels in adult patients with GH deficiency: a report from the NordiNet® International Outcome Study

Weber Matthias , Pedersen Birgitte Tonnes , Pournara Effie , Christiansen Jens Sandahl , Hoybye Charlotte

Introduction: The clinical significance of the impact of GH on glucose homeostasis in adults with GH deficiency (GHD) remains unclear. We report the impact of 4 years of continuous GH therapy on HbA1c and progression to diabetes.Methods: Data were analysed from patients with adult-onset GHD (>20 years old) enrolled in NordiNet® International Outcome Study (IOS) (NCT00960128), an observational study, and treated with GH (Norditropin<su...

ea0032oc6.3 | Diabetes &amp; Obesity | ECE2013

Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin–angiotensin–aldosterone system in healthy men

Skov Jeppe , Dejgaard Anders , Frokiaer Jorgen , Holst Jens Juul , Jonassen Thomas , Rittig Soren , Christiansen Jens Sandahl

Glucagon-like peptide-1 (GLP-1) is an incretine hormone with multiple actions besides control of glucose homeostasis. GLP-1 is known to cause natriuresis in humans but the effects on basic renal physiology are still partly unknown.This study therefore aimed to demonstrate the effects of GLP-1 on kidney hemodynamics, electrolyte handling, and the renin–angiotensin–aldosterone system in healthy men.Twelve healthy young male...

ea0032p464 | Diabetes | ECE2013

Effects of human insulin and insulin aspart preparations on levels of IGFI, IGFBPs and IGFI bioactivity in patients with type 1 diabetes

Ma Zhulin , Christiansen Jens Sandahl , Lauritzen Torsten , Parkner Tina , Laursen Torben , Frystyk Jan

Introduction: Type 1 diabetes (T1D) is characterized by primary insulin insufficiency and secondary disruption of GH–IGF–IGFBP axis. S.c. insulin therapy is necessary to normalize this axis. This study aimed to investigate whether the distinct insulin profiles obtained with insulin aspart and human insulin preparations, respectively, affect IGF1 concentration and bioactivity and IGFBP levels differently.Methods: In a randomized, four-period cro...

ea0022p375 | Endocrine Disruptors | ECE2010

Normal cortisol response to high dose Synacthen and insulin tolerance test in children and adults with Prader--Willi syndrome (PWS)

Farholt Stense , Sode-Carlsen Rasmus , Christiansen Jens Sandahl , Ostergaard John Rosendahl , Hoybye Charlotte

Objective: PWS is associated with hypogonadism and partial GH insufficiency. In addition partial insufficiency of the hypothalamic–pituitary–adrenal (HPA) axis recently was suggested (de Lind van Wijngaarden 2008) based upon an insufficient response to an overnight single-dose metyrapone in 15 out of 25 (60%) children. We aimed at further exploring this potentially dangerous condition.Methods: During a 1-year period genetically verified PWS pat...